APO RESEARCH · REPORT
Osteoporosis Drugs
Osteoporosis is a disease where decreased bone strength increases the risk of a broken bone. It is the most common reason for a broken bone among the elderly. Bones that commonly break include the back bones, the bones of the forearm, and the hip. Until a broken bone occurs there are typically no symptoms. Bones may weaken to such a degree that a break may occur with minor stress or spontaneously. Chronic pain and a decreased ability to carry out normal activities may occur following a broken bone.
Product & engineering
Understand the product.
Osteoporosis is a disease where decreased bone strength increases the risk of a broken bone. It is the most common reason for a broken bone among the elderly. Bones that commonly break include the back bones, the bones of the forearm, and the hip. Until a broken bone occurs there are typically no symptoms. Bones may weaken to such a degree that a break may occur with minor stress or spontaneously. Chronic pain and a decreased ability to carry out normal activities may occur following a broken bone.
Osteoporosis may be due to lower than normal peak bone mass and greater than normal bone loss. Bone loss increases after menopause due to lower levels of estrogen. Osteoporosis may also occur due to a number of diseases or treatments including alcoholism, anorexia, hyperthyroidism, surgical removal of the ovaries, and kidney disease. Certain medications increase the rate of bone loss including some antiseizure medications, chemotherapy, proton pump inhibitors, selective serotonin reuptake inhibitors, and steroids. Not enough exercise and smoking are also risk factors. Osteoporosis is defined as a bone density of 2.5 standard deviations below that of a young adult. This is typically measured by dual-energy X-ray absorptiometry at the hip.
Selected research
Industry Research
Osteoporosis Drugs Industry Research Report 2026
Market perspective
Osteoporosis is a disease where decreased bone strength increases the risk of a broken bone. It is the most common reason for a broken bone among the elderly. Bones that commonly break include the back bones, the bones of the forearm, and the hip. Until a broken bone occurs there are typically no symptoms. Bones may weaken to such a degree that a break may occur with minor stress or spontaneously. Chronic pain and a decreased ability to carry out normal activities may occur following a broken bone.
Osteoporosis may be due to lower than normal peak bone mass and greater than normal bone loss. Bone loss increases after menopause due to lower levels of estrogen. Osteoporosis may also occur due to a number of diseases or treatments including alcoholism, anorexia, hyperthyroidism, surgical removal of the ovaries, and kidney disease. Certain medications increase the rate of bone loss including some antiseizure medications, chemotherapy, proton pump inhibitors, selective serotonin reuptake inhibitors, and steroids. Not enough exercise and smoking are also risk factors. Osteoporosis is defined as a bone density of 2.5 standard deviations below that of a young adult. This is typically measured by dual-energy X-ray absorptiometry at the hip.
In Brazil, Osteoporosis Drugs key players include Eli Lilly, Novartis, Pfizer, etc. Global top three manufacturers hold a share over 35%.
Read the full market overview
In terms of product, Antiresorptive Drugs is the largest segment, with a share over 70%. And in terms of application, the largest application is Female, followed by Male.
Report Scope
This report quantifies the global Osteoporosis Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Osteoporosis Drugs Market by Company
Eli Lilly
Novartis
Pfizer
Amgen
Merck
Novo nordisk
Actavis
Roche
Osteoporosis Drugs Segment by Type
Antiresorptive Drugs
Anabolic Drugs
Osteoporosis Drugs Segment by Application
Female
Male
Osteoporosis Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Osteoporosis Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Osteoporosis Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Osteoporosis Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Osteoporosis Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Osteoporosis Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Osteoporosis Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Antiresorptive Drugs
- Anabolic Drugs
Applications
- Female
- Male
Companies covered
- Eli Lilly
- Novartis
- Pfizer
- Amgen
- Merck
- Novo nordisk
- Actavis
- Roche
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Osteoporosis Drugs Market Size (2021-2032)
- 2.2.2 Global Osteoporosis Drugs Sales (2021-2032)
- 2.2.3 Global Osteoporosis Drugs Market Average Price (2021-2032)
- 2.3 Osteoporosis Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Antiresorptive Drugs
- 2.3.3 Anabolic Drugs
- 2.4 Osteoporosis Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Female
- 2.4.3 Male
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Osteoporosis Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Osteoporosis Drugs Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Osteoporosis Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global Osteoporosis Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global Osteoporosis Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Osteoporosis Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Osteoporosis Drugs, Product Type & Application
- 3.8 Global Manufacturers of Osteoporosis Drugs, Established Date
- 3.9 Global Osteoporosis Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Eli Lilly
- 4.1.1 Eli Lilly Company Information
- 4.1.2 Eli Lilly Business Overview
- 4.1.3 Eli Lilly Osteoporosis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Eli Lilly Osteoporosis Drugs Product Portfolio
- 4.1.5 Eli Lilly Recent Developments
- 4.2 Novartis
- 4.2.1 Novartis Company Information
- 4.2.2 Novartis Business Overview
- 4.2.3 Novartis Osteoporosis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Novartis Osteoporosis Drugs Product Portfolio
- 4.2.5 Novartis Recent Developments
- 4.3 Pfizer
- 4.3.1 Pfizer Company Information
- 4.3.2 Pfizer Business Overview
- 4.3.3 Pfizer Osteoporosis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Pfizer Osteoporosis Drugs Product Portfolio
- 4.3.5 Pfizer Recent Developments
- 4.4 Amgen
- 4.4.1 Amgen Company Information
- 4.4.2 Amgen Business Overview
- 4.4.3 Amgen Osteoporosis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Amgen Osteoporosis Drugs Product Portfolio
- 4.4.5 Amgen Recent Developments
- 4.5 Merck
- 4.5.1 Merck Company Information
- 4.5.2 Merck Business Overview
- 4.5.3 Merck Osteoporosis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Merck Osteoporosis Drugs Product Portfolio
- 4.5.5 Merck Recent Developments
- 4.6 Novo nordisk
- 4.6.1 Novo nordisk Company Information
- 4.6.2 Novo nordisk Business Overview
- 4.6.3 Novo nordisk Osteoporosis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Novo nordisk Osteoporosis Drugs Product Portfolio
- 4.6.5 Novo nordisk Recent Developments
- 4.7 Actavis
- 4.7.1 Actavis Company Information
- 4.7.2 Actavis Business Overview
- 4.7.3 Actavis Osteoporosis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Actavis Osteoporosis Drugs Product Portfolio
- 4.7.5 Actavis Recent Developments
- 4.8 Roche
- 4.8.1 Roche Company Information
- 4.8.2 Roche Business Overview
- 4.8.3 Roche Osteoporosis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Roche Osteoporosis Drugs Product Portfolio
- 4.8.5 Roche Recent Developments
5 Global Osteoporosis Drugs Market Scenario by Region
- 5.1 Global Osteoporosis Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Osteoporosis Drugs Sales by Region: 2021-2032
- 5.2.1 Global Osteoporosis Drugs Sales by Region: 2021-2026
- 5.2.2 Global Osteoporosis Drugs Sales by Region: 2027-2032
- 5.3 Global Osteoporosis Drugs Revenue by Region: 2021-2032
- 5.3.1 Global Osteoporosis Drugs Revenue by Region: 2021-2026
- 5.3.2 Global Osteoporosis Drugs Revenue by Region: 2027-2032
- 5.4 North America Osteoporosis Drugs Market Facts & Figures by Country
- 5.4.1 North America Osteoporosis Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Osteoporosis Drugs Sales by Country (2021-2032)
- 5.4.3 North America Osteoporosis Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Osteoporosis Drugs Market Facts & Figures by Country
- 5.5.1 Europe Osteoporosis Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Osteoporosis Drugs Sales by Country (2021-2032)
- 5.5.3 Europe Osteoporosis Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Osteoporosis Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific Osteoporosis Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Osteoporosis Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Osteoporosis Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Osteoporosis Drugs Market Facts & Figures by Country
- 5.7.1 South America Osteoporosis Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Osteoporosis Drugs Sales by Country (2021-2032)
- 5.7.3 South America Osteoporosis Drugs Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.7.7 Colombia
- 5.8 Middle East and Africa Osteoporosis Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Osteoporosis Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Osteoporosis Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Osteoporosis Drugs Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Osteoporosis Drugs Sales by Type (2021-2032)
- 6.1.1 Global Osteoporosis Drugs Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Osteoporosis Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global Osteoporosis Drugs Revenue by Type (2021-2032)
- 6.2.1 Global Osteoporosis Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Osteoporosis Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global Osteoporosis Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Osteoporosis Drugs Sales by Application (2021-2032)
- 7.1.1 Global Osteoporosis Drugs Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Osteoporosis Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global Osteoporosis Drugs Revenue by Application (2021-2032)
- 7.2.1 Global Osteoporosis Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Osteoporosis Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global Osteoporosis Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Osteoporosis Drugs Value Chain Analysis
- 8.1.1 Osteoporosis Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Osteoporosis Drugs Production Mode & Process
- 8.2 Osteoporosis Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Osteoporosis Drugs Distributors
- 8.2.3 Osteoporosis Drugs Customers
9 Global Osteoporosis Drugs Analyzing Market Dynamics
- 9.1 Osteoporosis Drugs Industry Trends
- 9.2 Osteoporosis Drugs Industry Drivers
- 9.3 Osteoporosis Drugs Industry Opportunities and Challenges
- 9.4 Osteoporosis Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst